Patents Examined by Jegatheesan Seharaseyon
  • Diagnostic method for determining the presence and amount of human interleukin-3 in a sample using novel IL-3 antibodies
    Patent number: 9714286
    Abstract: For determining the presence and amount of human interleukin 3 (IL-3) in a sample, the present invention provides a diagnostic method, wherein an anti-IL-3-antibody, fragment or construct thereof is added to said sample under conditions which allow for binding said antibody, fragment or construct thereof to IL-3 and detecting the amount of antibody bound IL-3 in said sample, wherein the anti-IL-3-antibody is clone 13. Further subject matter of the present invention are the novel antibody clone 13, a nucleic acid encoding said antibody and a hybridoma cell line which produces antibody clone 13. A diagnostic assay kit contains all necessary reagents and materials for performing such assay, preferably an ELISA assay and especially preferably contains antibody clones 13 and 11.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: July 25, 2017
    Assignee: Universitätsklinikum Regensburg
    Inventors: Matthias Mack, Hilke Brühl, Kerstin Renner
  • Interferon-alpha fusion protein in which cytoplasmic transduction peptide and polyethylene glycol are bonded to one another
    Patent number: 9682152
    Abstract: The present invention relates to IFN-? fusion protein in which a cytoplasmic transduction peptide (CTP) and polyethylene glycol (PEG) are bonded to an IFN-? protein. The IFN-? fusion protein of the present invention is characterized in that the specific activity of interferon remains high, the half-life of the INF-? fusion protein is extended when delivered in vivo, and the mobility of the interferon in a liver is improved. The IFN-? fusion protein of the present invention can be used in the development of protein drugs effective in preventing or treating liver diseases, including various types of viral infections or the like.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: June 20, 2017
    Assignee: JW CREAGENE INC.
    Inventors: Yong Soo Bae, Seung Ho Hong, Young Hoon Kim, Seung Soo Han, Jin Kim
  • Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event
    Patent number: 9683038
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: June 20, 2017
    Assignee: Novartis AG
    Inventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
  • Diagnostic blood test for sarcoidosis
    Patent number: 9683999
    Abstract: Sarcoidosis is a multisystem disease characterized by granulomatous inflammation in affected organs. We have developed a blood test using mycobacterial catalase-peroxidase that has a high positive predictive value for confirming a diagnosis of sarcoidosis.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: June 20, 2017
    Inventor: David R. Moller
  • IL-1 binding proteins
    Patent number: 9670276
    Abstract: The disclosure provides binding proteins that specifically bind to IL-1? and IL-1?. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1? and/or IL-1? and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: June 6, 2017
    Assignee: AbbVie Inc.
    Inventors: Susan E. Lacy, Lorenzo Benatuil, Meha Chhaya, Emma Fung, Renee Miller, Ravi Chari, Sarah J. Heighton, Jacqueline G. Bixby
  • Activation of myeloid-derived suppressor cells as a predictor of patient response to interferon-A therapy
    Patent number: 9655950
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: May 23, 2017
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa Geskin, Oleg E. Akilov
  • Codon optimized sequence for an antiviral protein
    Patent number: 9644015
    Abstract: A codon optimized nucleic acid sequence for Interferon Alpha-2a is provided which can be used for expression of Interferon Alpha-2a in E. Coli.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: May 9, 2017
    Assignee: BIOGENOMICS LIMITED
    Inventors: Archana Rajesh Krishnan, Sanjay Madhukar Sonar, Damodar Krishnabahadur Thappa
  • Composition for preventing or alleviating atopic dermatitis comprising immunosuppressant and transglutaminase 2 inhibitor
    Patent number: 9642870
    Abstract: The present invention relates to a composition for preventing, treating or alleviating atopic dermatitis comprising an immunosuppressant and a transglutaminase 2 inhibitor as active ingredients. Conjoint administration of an immunosuppressant and a transglutaminase 2 inhibitor according to the present invention makes it possible to achieve far better therapeutic effects than with administration of either an immunosuppressant or a transglutaminase 2 inhibitor alone, since there is a reduction in the dose of an immunosuppressant which is difficult to administer for a long time because of side effects and with which, when discontinued, lesions are liable to become exacerbated to the original state, and since an immunosuppressant is mixed with a transglutaminase 2 inhibitor which in some patients has a lackluster effect in treating atopic dermatitis.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: May 9, 2017
    Assignee: Dongguk University Industry-Academic Cooperation Foundation
    Inventor: Ai-Young Lee
  • Modified animal erythropoietin polypeptides and their uses
    Patent number: 9644014
    Abstract: Modified animal erythropoietin polypeptides and uses thereof are provided.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: May 9, 2017
    Assignees: Ambrx, Inc., Eli Lilly and Company
    Inventors: Feng Tian, Anna-Maria A. Hays Putnam, Frank Song, Stephanie Chu, Joseph Sheffer, Richard S. Barnett, Marc Siladi, Kyle Atkinson, Darin Lee, Peter C. Canning
  • Method for reducing injury and stabilizing muscle using orally administered interferon
    Patent number: 9642893
    Abstract: The present disclosure is directed to compositions and methods for treating or preventing muscle injury or diseases through oral administration of low doses of type I and/or type III interferons. In one embodiment a composition is administered comprising interferon-alpha and trehalose.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 9, 2017
    Inventor: Joseph Cummins
  • Oral composition containing interferon-?
    Patent number: 9629900
    Abstract: The present invention provides oral compositions which contain interferon ? (IFN?) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFN? of the present invention can produce a sufficient effect even when administered at a very low dose. Furthermore, the compositions of the present invention can also be readily administered to animals such as dogs by formulating them into feed or such.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: April 25, 2017
    Assignees: Hokusan Co. Ltd., National Institute of Advanced Industrial Science and Technology
    Inventors: Kuniaki Yoshioka, Ko Sato, Toru Gotanda, Akira Ito, Emiko Isogai, Kazuaki Takehara, Nobutoshi Maehara
  • Fusions of antibodies to CD38 and attenuated interferon alpha
    Patent number: 9611322
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: April 4, 2017
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • Blockage of interferon-gamma for prevention of polymicrobial synergy
    Patent number: 9598488
    Abstract: The present invention is directed to methods for treating a viral respiratory infection in a subject, preventing polymicrobial synergy in a subject, or preventing a bacterial infection in a subject. These methods include selecting a subject with a viral respiratory infection, a subject susceptible to polymicrobial synergy, or a subject susceptible to bacterial infection, respectively. In each case a therapeutic agent that inhibits interferon-gamma (IFN?) is provided and administered to the selected subject under conditions effective to treat the viral respiratory infection, to prevent polymicrobial synergy, or to prevent a bacterial infection, respectively.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: March 21, 2017
    Assignee: Albany Medical College
    Inventors: Dennis W. Metzger, Keer Sun
  • Derivatisation of erythropoietin (EPO)
    Patent number: 9579393
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: February 28, 2017
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Antibody with specificity for GM-CSF (I)
    Patent number: 9567397
    Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: February 14, 2017
    Assignee: MERCK SERONO S.A.
    Inventors: Laurent Magnenat, Olivier Leger, Charles Mackay, David Georges Zahra
  • Mono- and di-peg IL-10 production; and uses
    Patent number: 9566345
    Abstract: Provided are methods of producing mono- and di-pegylated IL-10.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: February 14, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven J. Blaisdell, Collette M. Cutler, Brittany C. Paporello, Alexandre Ambrogelly
  • Antibody with specificity for GM-CSF (II)
    Patent number: 9567398
    Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: February 14, 2017
    Assignee: MERCK SERONO S.A.
    Inventors: Laurent Magnenat, Olivier Leger, Charles MacKay, David Georges Zahra
  • Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3a/C4a, immunoglobulins and chemotactic factors
    Patent number: 9555084
    Abstract: The present invention refers to a combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3a/C4a, immunoglobulins and chemotactic factors. The invention also relates to a process for the preparation of said combination from serum, placenta or colostrum and to composition containing said combination for use in the treatment of conditions requiring tissue repair and regeneration and for the substitution of stem cell therapies.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: January 31, 2017
    Assignee: INNOMED S.A.
    Inventors: Alberto Bartorelli, Maria Rosa Gobbi
  • Derivatisation of erythropoietin (EPO)
    Patent number: 9549990
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: January 24, 2017
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Treatment of thrombocytopenia using orally administered interferon
    Patent number: 9526694
    Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: December 27, 2016
    Assignee: Amarillo Biosciences, Inc.
    Inventors: Martin Joseph Cummins, Chau-Ting Yeh, Ching-Yuan Lee